Find News

Filter articles

Applied Filters

Showing 91 to 100 of 225 results

AstraZeneca to divest Rhinocort Aqua rights outside US


AstraZeneca and Cilag, an affiliate of Johnson & Johnson, have entered into an agreement for AstraZeneca to divest the rights to Rhinocort Aqua outside the US.

$2m worth of fake drugs seized in Myanmar


Myanmar authorities have seized K2.8 billion worth of counterfeit and expired drugs.

Glenmark partners with Particle Sciences in Abraxane generic deal


India-based pharmaceutical company Glenmark has signed a wide-ranging drug agreement with Particle Sciences, a provider of drug development services.

Teva and Regeneron partner in $250m deal


Teva and Regeneron Pharmaceuticals have combined to develop and commercialise fasinumab, a novel nerve growth factor (NGF) antibody.

AIPPI 2016: Pay-for-delay deals come in for scrutiny

Japan, US20-09-2016

Pharmaceutical pay-for-delay deals worth less than around $10 million are unlikely to be challenged by the authorities in US courts, according to a speaker at the 2016 AIPPI World Congress in Milan.

Pfizer sues Sun Pharma for patent infringement


Pfizer has sued Indian generic company Sun Pharma for allegedly infringing patents centring on Xeljanz, a treatment for rheumatoid arthritis.

Japan issues post-Brexit R&D warning to UK

Japan, UK08-09-2016

Japan’s government officials have warned the UK that the Asian country may reconsider its research and development activities in the UK following Brexit.

Chugai and Fuji Pharma enter agreement over cancer drug


Chugai Pharmaceutical and Fuji Pharma have entered into an agreement to transfer the rights to the manufacture and marketing of cancer drug Vesanoid in Japan.

AstraZeneca to pay $5.5m in bribery case

China, Russia, US31-08-2016

UK-based company AstraZeneca will have to pay $5.5 million to resolve a bribery case after allegedly falsely rewarding healthcare officials in China and Russia.

Mylan biosimilar application moves forward

India, UK26-08-2016

The European Medicines Agency has accepted pharmaceutical company Mylan’s request to review its application for a biosimilar of Herceptin.

Showing 91 to 100 of 225 results